<DOC>
	<DOC>NCT00564941</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload</brief_summary>
	<brief_title>Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Inclusion criteria: In or outpatients with myelodysplasia / with risk of low or intermedier1 according to the International Prognostic Scoring System (IPSS) confirmed by bone marrow evaluation within 3 month/ or beta thalassaemia major patients, who have chronic iron overload, as a consequence of frequent blood transfusion Serum ferritin&gt; 1800 Âµg/L Age: 1880 years men and women Chronic iron overload caused by at least 30 units and maximum 100 units of blood of packed red blood cells Deferoxamin therapy is contraindicated or inadequate or unable to use in the recommended dose due to intolerability or other reason Eastern Cooperative Oncology Group (ECOG) performance status score between 02 written informed consent Exclusion criteria: beta thalassaemia minor, haemosiderosis caused by other than chronic transfusional iron overload, patients with impaired renal function (Creatinin clearance&lt; 60 ml/ min), pregnancy, lactation, patient of childbearing potential unwilling to use contraceptive precautions known hypersensitivity to deferasirox or any ingredients, impaired hepatic function (SGOT,SGPT 5x above UNL). Patients severely ill due to underlying disease progression or other severe concomitant disease. Patients with poor prognosis of karyotype patients with malabsorption caused by inflammatory bowel disease, gastrectomy, pancreatitis or other medical condition History of nephrotic syndrome Significant proteinuria Patients with a previous history of clinically relevant ocular toxicity related to iron chelation Patients with positive test to HIV Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>beta-Thalassemia</keyword>
	<keyword>Iron Overload</keyword>
	<keyword>Iron Chelating Agents</keyword>
	<keyword>deferasirox</keyword>
</DOC>